Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Acquires $34,600.00 in Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) insider William Benton Jones bought 20,000 shares of Corvus Pharmaceuticals stock in a transaction on Monday, May 6th. The stock was purchased at an average price of $1.73 per share, for a total transaction of $34,600.00. Following the completion of the acquisition, the insider now owns 153,773 shares in the company, valued at approximately $266,027.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Corvus Pharmaceuticals Trading Down 12.0 %

Corvus Pharmaceuticals stock traded down $0.23 during midday trading on Tuesday, reaching $1.68. The stock had a trading volume of 1,011,849 shares, compared to its average volume of 221,137. The company has a market capitalization of $82.39 million, a P/E ratio of -3.00 and a beta of 1.05. Corvus Pharmaceuticals, Inc. has a 12 month low of $1.05 and a 12 month high of $4.19. The company has a fifty day moving average price of $1.79 and a two-hundred day moving average price of $1.78.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Tuesday, March 19th. The company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). On average, equities research analysts predict that Corvus Pharmaceuticals, Inc. will post -0.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on CRVS. Oppenheimer increased their target price on Corvus Pharmaceuticals from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Monday, April 1st. Finally, Mizuho reiterated a “neutral” rating and set a $3.50 price target on shares of Corvus Pharmaceuticals in a report on Wednesday, March 27th.

Hedge Funds Weigh In On Corvus Pharmaceuticals

An institutional investor recently raised its position in Corvus Pharmaceuticals stock. Towerview LLC increased its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 67.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 342,478 shares of the company’s stock after purchasing an additional 137,478 shares during the period. Corvus Pharmaceuticals accounts for 0.3% of Towerview LLC’s portfolio, making the stock its 18th largest holding. Towerview LLC owned 0.70% of Corvus Pharmaceuticals worth $500,000 at the end of the most recent quarter. 46.64% of the stock is currently owned by institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.